Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Altimmune (ALT) over the last 14 years, with Q3 2025 value amounting to $27000.0.

  • Altimmune's Depreciation and Depletion fell 2702.7% to $27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $119000.0, marking a year-over-year decrease of 6520.47%. This contributed to the annual value of $238000.0 for FY2024, which is 5240.0% down from last year.
  • As of Q3 2025, Altimmune's Depreciation and Depletion stood at $27000.0, which was down 2702.7% from $30000.0 recorded in Q2 2025.
  • Altimmune's Depreciation and Depletion's 5-year high stood at $200000.0 during Q4 2021, with a 5-year trough of $27000.0 in Q3 2025.
  • Over the past 5 years, Altimmune's median Depreciation and Depletion value was $100000.0 (recorded in 2021), while the average stood at $87028.1.
  • As far as peak fluctuations go, Altimmune's Depreciation and Depletion surged by 10000.0% in 2021, and later crashed by 7591.24% in 2024.
  • Quarter analysis of 5 years shows Altimmune's Depreciation and Depletion stood at $200000.0 in 2021, then tumbled by 50.0% to $100000.0 in 2022, then skyrocketed by 37.0% to $137000.0 in 2023, then tumbled by 75.91% to $33000.0 in 2024, then fell by 18.18% to $27000.0 in 2025.
  • Its Depreciation and Depletion stands at $27000.0 for Q3 2025, versus $30000.0 for Q2 2025 and $29000.0 for Q1 2025.